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Role of alpha-synuclein in autophagy modulation
of primary human T lymphocytes
T Colasanti1,2,12, M Vomero1,12, C Alessandri3, C Barbati1,4, A Maselli1, C Camperio5, F Conti3, A Tinari6, C Carlo-Stella7,8, L Tuosto5,
D Benincasa9,10, G Valesini3, W Malorni*,4,11,13, M Pierdominici1,13 and E Ortona1,4,13
It has been demonstrated that a-synuclein can aggregate and contribute to the pathogenesis of some neurodegenerative
diseases and it is capable of hindering autophagy in neuronal cells. Here, we investigated the implication of a-synuclein in
the autophagy process in primary human T lymphocytes. We provide evidence that: (i) knocking down of the a-synuclein gene
resulted in increased autophagy, (ii) autophagy induction by energy deprivation was associated with a significant decrease
of a-synuclein levels, (iii) autophagy inhibition by 3-methyladenine or by ATG5 knocking down led to a significant increase of
a-synuclein levels, and (iv) autophagy impairment, constitutive in T lymphocytes from patients with systemic lupus
erythematosus, was associated with abnormal accumulation of a-synuclein aggregates. These results suggest that a-synuclein
could be considered as an autophagy-related marker of peripheral blood lymphocytes, potentially suitable for use in the clinical
practice.
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Synucleins are a family of soluble proteins common to
vertebrates known to be expressed in neural crest-derived
cells (neuronal cells, neuroglial cells and melanocytic cells)
and in certain tumors.1 In particular, the most studied
synuclein, that is, the a-synuclein, is primarily found in
neuronal tissue but also in other cell types including peripheral
blood lymphocytes.2,3 Alpha-synuclein exists in monomers
and oligomers that, in neurodegenerative disorders such as
Parkinson’s Disease (PD), dementia with Lewy bodies and
multiple system atrophy, have been demonstrated to form
insoluble fibril aggregates.4,5 In these disorders, known as
synucleinopathies, macroautophagy (hereafter referred to as
autophagy), the form of intracellular phagocytosis in which a
cell actively consumes and recycles damaged organelles or
misfolded proteins by encapsulating them into autophago-
somes,6,7 seems to have a key pathogenetic role. In
particular, it has been suggested that the complex framework
of events leading to autophagic process could be defective in
these diseases so that abnormal a-synuclein protein aggre-
gates are formed and accumulate.8,9 Conversely, it has
strikingly been observed that a-synuclein overexpression is
capable of hindering autophagy at a very early stage of
autophagosome formation.10 To date, however, all these
important insights are derived from studies carried out in
neuronal cells, and the implication of a-synuclein in autophagy
modulation in cells other than neurons has not been
investigated yet. In particular, as autophagy process has a
fundamental role in the immune system integrity and function,
including lymphocyte differentiation and metabolism, we
decided to investigate whether a-synuclein could be involved
in the lymphocyte autophagy.11 In fact, the impairment of
autophagy has been recently linked to several immune-
mediated diseases such as systemic lupus erythematosus
(SLE).12–16 To note, an increased level of a-synuclein in T
lymphocytes from patients with SLE, resistant to autophagy
induction, has been reported.16 In this study, we provide
evidence that a-synuclein can actually be considered as a key
player in the mechanism of autophagy of primary human T
lymphocytes, suggesting a clinical application of this molecule
for monitoring autophagy level in freshly isolated T cells.
Results
On the role of a-synuclein in T-lymphocyte autophagy
Alpha-synuclein silencing increases autophagy levels in T
lymphocytes: Alpha-synuclein has been reported as a
negative regulator of autophagy in neuronal cells.10 More
recently, we relieved an increased level of a-synuclein
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expression in T lymphocytes from patients with SLE, a
disease characterized by autophagy impairment, in compar-
ison with that detected in T lymphocytes from healthy
subjects.16 Hence, we asked if this molecule could have a
regulatory function in the autophagy of T lymphocytes. To
this purpose, we decided to transfect these cells with specific
siRNA to knock down a-synuclein gene. In our experimental
conditions, 24 h after siRNA addition, a-synuclein expression
decreased by about 50%, as assessed by both flow
cytometry (Figures 1a and b) and western blot (Figures 1c
and d) analyses, whereas LC3-II levels significantly
increased in comparison with control siRNA-transfected
(þ 44%) and non-transfected (þ 64%) cells (Po0.01 in both
cases; Figures 1e and f). In order to assess the rate of
autophagosome formation (i.e., autophagic flux), we also
analyzed LC3-II levels in the presence of the lysosomal
protease inhibitors E64d and pepstatin A, which block LC3-II/
autophagosome degradation.17 In the presence of these
inhibitors, we observed a further increase of LC3-II levels in
a-synuclein siRNA-transfected T cells (Figures 1e and f).
Accordingly, p62 protein, another accredited marker of
autophagy that accumulates when autophagy is inhibited
and decreases when autophagy is induced,18 was decreased
by about 75% in a-synuclein siRNA-transfected T cells
as compared with control siRNA-transfected and non-
transfected T cells (Po0.01 in both cases; Figures 1g and h).
This significant decrease of p62 levels was not detectable in
a-synuclein siRNA-transfected T cells when the lysosomal
protease inhibitors E64d and pepstatin A were added
(Figures 1g and h).
In order to further characterize these results, ultrastructural
analyses were carried out at the transmission electron
microscope. The presence of autophagic vacuoles containing
structures that can clearly be identified as cytoplasmic, such
as partially degraded endoplasmic reticulum and cell debris,
was observed in a-synuclein knocked down T cells (Figure 1i).
Morphometric evaluation of these samples, as stated in
Materials and methods section, indicated that the percentage
of cells with clear signs of autophagy was significantly higher
(þ 23%) in a-synuclein knocked down T cells in comparison
with control siRNA-transfected T cells. All in all, the current set
of experiments suggested that a-synuclein could have a direct
inhibitory role in T-cell autophagy.
On the role of autophagy in a-synuclein degradation in
T lymphocytes
Induction of autophagy leads to a-synuclein degradation:
Alpha-synuclein has been reported to form fibrillary aggre-
gates in metabolic impairment conditions.19 Autophagy has
been demonstrated to be particularly important for the
clearance of these aggregates as it is the only intracellular
proteolytic system capable of eliminating insoluble or
aggregated a-synuclein forms.9 The signals triggering for
the autophagic degradation of a-synuclein could be asso-
ciated with the ‘intrinsic’ status of the protein, that is, its
folding state, the presence of post-translational modifications
(e.g., ubiquitination) and its solubility.8,9 In this study, in order
to evaluate if autophagy could interfere with the a-synuclein
level and degradation of aggregates, T lymphocytes were
cultured under growth factor deficiency (serum starvation), a
condition that is known to induce metabolic impairment and
to trigger autophagy. Alpha-synuclein analyzed by SDS-
PAGE showed bands at different molecular weights
(Figure 2a). Interestingly, we observed that the levels of
the 14- and the 70-kDa bands varied in cells undergoing
autophagy. Hence, we focused on the 14-kDa band, which is
consistent with the monomeric size, and on the 70-kDa band,
which is consistent with an aggregate form susceptible to
autophagy degradation (Figures 2b and c). T lymphocytes
cultured in 1% FBS showed significant decreased levels of
a-synuclein (both the monomeric form and the aggregates)
compared with those observed in T lymphocytes cultured in
10% FBS ( 51% for the14-kDa a-synuclein, and  75% for
the 70-kDa a-synuclein, Po0.01 in both cases; Figures 2a–c).
Accordingly, LC3-II levels resulted significantly increased
in cells under serum starvation (þ 55%, P¼ 0.008,
Figures 2d and e), whereas p62 levels significantly
decreased ( 60%, P¼ 0.007, Figures 2f and g). In the
presence of the lysosomal protease inhibitors E64d and
pepstatin A, LC3-II levels further increased (þ 32%,
Figures 2d and e) and p62 returned to basal levels
(Figures 2f and g). Moreover, in the same experimental
conditions, we detected a significant increase of a-synuclein
levels by western blot analysis (Figures 2a–c) and an
accumulation of a-synuclein into the autophagosomes by
immunofluorescence (Figure 2h, high-magnification micro-
graph is provided in Supplementary Figure 1), clearly
indicating that the degradation of this protein occurred by
the autophagy process. Altogether, these results indicate
that under metabolic impairment T lymphocytes from healthy
subjects undergo an active and functional autophagy
providing the prompt degradation of a-synuclein aggregates.
Alpha-synuclein oligomers have been demonstrated to
accumulate in neurons from patients with neurodegenerative
diseases, such as PD, characterized by an autophagy
impairment. However, to date, no data have been reported
about a-synuclein levels in T lymphocytes from these patients,
including PD patients. We thus analyzed freshly isolated
T cells from PD patients under autophagic stimulation, that is,
under metabolic impairment. A ‘normal’ ability to clear
a-synuclein aggregates, comparable to that observed in
lymphocytes from healthy subjects, was observed in these
cells (Supplementary Figure 2).
Autophagy impairment leads to accumulation of a-synuclein
aggregates: As stated above and recently reported,16
T lymphocytes from SLE patients have been observed to be
resistant to autophagy induction, also displaying an upregula-
tion of genes negatively regulating autophagy, including
a-synuclein. Basing on these observations, we proceeded to
test whether this defective autophagy may account for
accumulation of a-synuclein aggregates. We cultivated under
serum starvation T lymphocytes from patients with SLE and,
as expected, we did not observe any change in LC3-II and p62
levels (Figures 3a–c). Interestingly, in these experimental
conditions, a significantly higher level of the aggregate form of
a-synuclein in comparison with that observed in T lymphocytes
cultured in 10% FBS was detected (þ 52%, P¼ 0.008,
Figures 3d and f). No significant changes were observed for
the monomeric 14 kDa a-synuclein (Figures 3d and e).
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Figure 1 Alpha-synuclein (a-syn) silencing in T lymphocytes. (a) Flow cytometry analysis of a-syn expression 24 h after siRNA transfection. Isotype control (ctr) staining is
represented by the dotted line. Non-transfected (untreated) anti-a-syn-labeled T lymphocytes are represented by the broken line, those transfected with ctr siRNA by the gray-
solid line, and those transfected with a-syn siRNA by the black-solid line. A representative experiment out of five is shown. (b) Values of a-syn/isotype ctr mean fluorescence
intensity ratio are reported. *Po0.05 versus other experimental conditions. (c) Western blot of cell lysates obtained from T lymphocytes non-transfected (untreated),
transfected with ctr siRNA and transfected with a-syn siRNA. Blots shown are representative of five independent experiments. (d) Densitometry analysis of monomeric a-syn
levels relative to b-actin is shown. Values are expressed as means±S.D. *Po0.05 versus other experimental conditions. (e) Western blot analysis of LC3-II in T lymphocytes
treated as follows: (i) non-transfected (untreated), (ii) transfected with ctr siRNA, (iii) transfected with a-syn siRNA and (iv) transfected with a-syn siRNA in the presence of
E64d and pepstatin A (Pep A). Blots shown are representative of five independent experiments. (f) Densitometry analysis of LC3-II levels relative to b-actin is shown. Values
are expressed as means±S.D. *Po0.05. (g) Western blot analysis of p62 in T lymphocytes (i) non-transfected (untreated), (ii) transfected with ctr siRNA,
(iii) transfected with a-syn siRNA and (iv) transfected with a-syn siRNA in the presence of E64d and Pep A. Blots shown are representative of five independent experiments.
(h) Densitometry analysis of p62 levels relative to b-actin is shown. Values are expressed as means±S.D. *Po0.05 versus other experimental conditions. (i) Transmission
electron micrographs representative of T cells transfected with a-syn siRNA (left and middle panels) and with ctr siRNA (right panel). Note the presence of typical autophagic
vacuoles in a-syn siRNA-transfected T cells (left). At high magnification (middle panel), degraded membranes and cell debris are visible in the vacuoles. The arrow indicates a
double membrane. FITC, fluorescein-5-isothiocyanate; MFI, mean fluorescence intensity
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Figure 2 Alpha-synuclein (a-syn) degradation by autophagy in T lymphocytes. (a) Western blot analysis of a-syn expression in T lymphocytes cultured with (i) 10% FBS,
(ii) 1% FBS and (iii) 1% FBS plus lysosomal inhibitors E64d and pepstatin A (Pep A). Blots shown are representative of five independent experiments. The bands of a-syn at
14 kDa (monomeric form) and at 70 kDa (aggregate form) are indicated by the arrows. Densitometry analysis of (b) the monomeric form of a-syn at 14 kDa (a-syn 14 kDa/b-
actin) and of (c) the aggregate form of a-syn at 70 kDa (a-syn 70 kDa/b-actin) are shown. Values are expressed as means±S.D. *Po0.05 for T lymphocytes cultured with 1%
FBS versus other experimental conditions. (d) Western blot analysis of LC3-II levels in T lymphocytes cultured with (i) 10% FBS, (ii) 1% FBS and (iii) 1% FBS plus E64d and
Pep A. Blots shown are representative of five independent experiments. (e) Densitometry analysis of LC3-II levels relative to b-actin (means±S.D.). *Po0.05 for
T lymphocytes cultured with 1% FBS versus other experimental conditions. (f) Western blot analysis of p62 levels in T lymphocytes cultured with (i) 10% FBS, (ii) 1% FBS and
(iii) 1% FBS plus E64d and Pep A. Blots shown are representative of five independent experiments. (g) Densitometry analysis of p62 levels relative to b-actin (means±S.D.).
*Po0.05. (h) Immunofluorescence analysis of a-syn localization in the presence of lysosomal inhibitors. Alpha-synuclein expression (red fluorescence) and LC3-II expression
(green fluorescence) in Triton X-100-permeated cells: T lymphocytes cultured with 10% FBS (left panels), 1% FBS (middle panels), 1% FBS plus E64d and Pep A (right
panels). Cells were stained with Hoechst dye to reveal nuclei (blue staining). Note the high number of yellow spots suggesting an accumulation of a-syn into autophagosomes
in the presence of lysosomal inhibitors (right panel). No yellow spots are instead observable in T lymphocytes cultured with 10% FBS. Magnification:  3000
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Figure 3 Defective autophagy and a-synuclein (a-syn) accumulation in T lymphocytes. (a) Western blot analysis of LC3-II and p62 levels in T lymphocytes from patients
with SLE cultured with (i) 10% FBS, (ii) 1% FBS and (iii) 1% FBS plus E64d and pepstatin A (Pep A). Blots shown are representative of 10 independent experiments.
Densitometry analysis of LC3-II levels (b) and of p62 levels (c) relative to b-actin. Values are expressed as means±S.D. (d) Western blot analysis of a-syn expression in SLE
T lymphocytes cultured with (i) 10% FBS, (ii) 1% FBS and (iii) 1% FBS plus E64d and pepstatin A. Blots shown are representative of 10 independent experiments. The bands
of a-syn at 14 kDa (monomeric form) and at 70 kDa (aggregate form) are indicated by the arrows. Densitometry analyses of the monomeric form of a-syn at 14 kDa (e) and of
the aggregate form of a-syn at 70 kDa (f) are shown. Values are expressed as means±S.D. *Po0.05. (g) Western blot analysis of a-syn in T lymphocytes from healthy
donors (HD) and SLE patients cultured with 1% of FBS. T lymphocytes from HD were cultured in the presence or absence of 3-methyladenine (3-MA). Blots shown are
representative of three independent experiments. Densitometry analysis of a-syn at 14 kDa (h) and at 70 kDa (i) relative to b-actin is shown. Values are expressed as
means±S.D. *Po0.05 versus other experimental conditions. (j) Western blot of a-syn expression in cell lysates obtained from T lymphocytes transfected with control (ctr)
siRNA or with ATG5 siRNA. Blots shown are representative of three independent experiments. Densitometry analysis of a-syn at 14 kDa (k) and at 70 kDa (l) relative to b-actin
is shown. Values are expressed as means±S.D. *Po0.05 versus other experimental conditions
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The lack of increased LC3-II levels under autophagic
stimulation in T lymphocytes from SLE patients could be
due either to an autophagy defect or, as suggested in other
experimental settings,17 to a very high lysosomal degradation
capacity leading to a prompt disappearance of LC3-II. To
clarify this point, serum starvation experiments, in the
presence of the lysosomal protease inhibitors E64d and
pepstatin A, were performed. At variance with T lymphocytes
from healthy subjects, LC3-II levels remained unchanged in
SLE T lymphocytes. Furthermore, under serum starvation, the
levels of p62 and of the monomeric and aggregated forms of
a-synuclein remained unchanged even in the presence of
E64d and pepstatin A (Figures 3a–f). These results seem to
suggest an autophagy defect in T cells from SLE patients
(Figures 3a–c). Notably, the treatment of T lymphocytes from
healthy donors with the autophagy inhibitor 3-methyladenine,
under serum starvation, led to a significant increase of
a-synuclein (Po0.01, Figures 3g–i), mimicking the condition
observed in SLE lymphocytes. To further demonstrate the
specific role of autophagy in a-synuclein degradation, we
inhibited the autophagic process knocking down ATG5 by
specific siRNA in T lymphocytes. Also in these conditions we
observed a significant LC3-II reduction (Po0.01, data not
shown) and a significant increase of a-synuclein levels
(þ 54% for the 14 kDa a-synuclein, and þ 62% for the
70 kDa a-synuclein, Po0.01 in both cases; Figures 3j–l),
strongly supporting the assumption that a defective auto-
phagy leads to the accumulation of a-synuclein aggregates.
Alpha-synuclein as an autophagy-related marker in
primary human T lymphocytes. Monitoring autophagy
in vivo or in organs is a poorly developed investigation area
at present.18 To verify the potential value of a-synuclein as an
autophagy-related marker in freshly isolated T lymphocytes,
we examined these cells for LC3-II and the monomeric form of
a-synuclein by western blot, and evaluated the possible
correlation between these two parameters. The time required
for isolation of lymphocytes was constant (2–3 h) in all
subjects, and biological samples were isolated and studied
immediately after blood drawing. As shown in Figures 4a and b,
a high interindividual variability for both a-synuclein and
LC3-II levels was present in T lymphocytes. Interestingly,
we found a significant inverse correlation between
a-synuclein and LC3-II levels (r¼  0.55, Po0.0001,
Figure 4c), suggesting the possibility to use a-synuclein as
straightforward autophagy-related marker in T lymphocytes
and immunopathology studies. Unexpectedly, the analysis of
p62 and of the p62-like protein NBR1 in freshly isolated
T lymphocytes failed to reveal any correlation with either
LC3-II or a-synuclein levels, denying the usefulness of
these proteins as markers to evaluate basal autophagy in
T lymphocytes and suggesting that the expression levels of
p62 and NBR1 can also be changed independently of
autophagy (Supplementary Figure 3).17
The possibility of using a-synuclein as an autophagy-related
marker was also demonstrated through the measurement of
a-synuclein levels in T lymphocytes from lymphoma patients
before and after 1 month of therapy with an autophagy
modulator, that is, the multikinase inhibitor sorafenib.20 This
study was embedded in a phase II clinical trial studying the
safety and activity of sorafenib in patients with relapsed or
refractory lymphoproliferative disorders.21 Guidetti and co-
workers found that LC3-II levels at baseline were significantly
higher in responsive patients than in non-responsive patients
and peripheral lymphocytes from the responsive patients
showed a significant reduction in LC3-II levels after 1 month of
therapy.21 Hence, LC3-II represents a predictive marker
associated with a favorable outcome of lymphoma patients
treated with sorafenib. Here, we found that changes of LC3-II
levels were paralleled by changes in a-synuclein levels,
assigning also to a-synuclein a role as predictive marker of
treatment efficacy (Figures 4d and e).
Discussion
We provide evidence that a-synuclein could be considered as
a key player in the mechanism of autophagy of primary human
T lymphocytes. Our results indicate that: (i) a-synuclein could
be considered as a ‘negative regulator’ of autophagy, (ii) the
aggregated form of a-synuclein, once formed, can be
degraded by autophagy in T lymphocytes from healthy
subjects but, (iii) alterations of this degradative molecular
pathway, as it occurs in SLE, can result in the abnormal
accumulation of a-synuclein, which, as in neurons,22 may
represent both a cause and a consequence of impaired
autophagic process and, finally, (iv) a-synuclein could
represent a valuable tool for the evaluation of autophagy in
primary T lymphocytes.
The study of autophagy in primary lymphocytes, although of
great interest in translational medicine, has scantily been
developed partially because they represent a very complex
cell type for the study of this process.16,21,23–25 Actually,
primary lymphocytes display a series of pitfalls due, among
others, to: (i) the presence of different subpopulations with
distinct features and functions, (ii) the activation processes
which modify their function, (iii) the difficulties in culturing
these cells and (iv) the peculiar very high nuclear/cytoplasmic
ratio, that is, the very small cytoplasmic milieu.
All in all, this is the first demonstration of the close link
between a-synuclein and autophagy in human primary T
lymphocytes. Alpha-synuclein seems to act as a negative
regulator, as demonstrated by experiments carried out with
siRNA to knock down a-synuclein gene. In fact, in these
experimental conditions, autophagy-related markers were
found significantly increased. Importantly, blocking LC3-II/
autophagosome degradation by using lysosomal protease
inhibitors,17 we observed a further increase of LC3-II levels in
a-synuclein knocked down T cells. This clearly suggests that
the increased LC3-II levels were not due to an alteration of the
lysosomal degradation pathway. A second important point
deals with the double-edged role of a-synuclein, that is, with
the assumption that it may represent both a cause and a
consequence of impaired autophagic process.9 On one hand,
it could be hypothesized that autophagy contributes to
a-synuclein turnover, and alterations of this proteolytic path-
way may result in a-synuclein accumulation because of its
impaired clearance. This was evident in T lymphocytes from
SLE patients where a resistance to autophagy induction,
previously observed,16 has now been better characterized.
This autophagy defect appeared to be associated to an
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accumulation of a-synuclein aggregates. Notably, in the
presence of lysosomal inhibitors, no significant changes in
the levels of both LC3-II and a-synuclein aggregates were
detected. This was probably determined by a block of the
autophagy process before autophagosome formation occur-
ring in T cells from SLE patients. Further studies appear,
however, mandatory in order to point out the specific step in
which autophagy is defective in these cells.
On the other hand, increased a-synuclein protein burden
may impair autophagy, generating thus a bidirectional
positive feedback loop. Consistently with our results,
Winslow et al.10 demonstrated that a-synuclein overexpres-
sion impairs autophagy. These authors, by the use of
different cultured cell lines (that is, human neuroblastoma
cells, SKNSH and human cervical carcinoma cells, HeLa),
found a mechanistic basis of the connection between
a-synuclein and autophagy via Rab1a inhibition that causes
mislocalization of the autophagy protein Atg9, and
decreases autophagosome formation. More recently, Song
et al.,26 using rat PC12 cells, showed that a-synuclein could
also impair autophagy by binding to and blocking the high-
mobility group box 1, a protein that has been described to
promote autophagy.27 It is conceivable that similar mechan-
isms could take place also in freshly isolated T cells,
although no data are available in this regard yet.
A further important point in this scenario is referred as to
T-cell apoptotic susceptibility. In fact, the balance between
autophagy and apoptosis, that is, the cross talk between these
two pathways, could be pivotal in determining cell fate.28,29 In
particular, T lymphocytes from patients with SLE are known to
display an enhanced spontaneous apoptosis and an autop-
hagic resistance.16,30 On the basis of our results, obtained
either in freshly isolated cells from healthy donors or from
patients with SLE, the hypothesis that a-synuclein could
represent an important molecule involved in both these
processes with opposite functions cannot be ruled out.
In the present work, we also demonstrate that, thanks to its
role in the autophagic process, a-synuclein may represent a
useful marker to evaluate autophagy in T lymphocytes
isolated from peripheral blood. This finding could be of
importance from a clinical point of view. In fact, drugs that
potentially modulate autophagy, such as the mTOR inhibitors
(rapamycin and derivatives), are increasingly being used in
clinical trials, and screenings are being performed for new
drugs that can modulate autophagy for therapeutic purposes,
particularly in immune-mediated diseases.13,31,32 Clearly, it is
important to determine whether these drugs are truly affecting
autophagy based on a set of accepted criteria and the use of
multiple and valuable markers has been recommended.18
Hence, on the basis of our results, we can suggest that
Figure 4 Alpha-synuclein (a-syn) expression and autophagy in freshly isolated T lymphocytes. (a) Alpha-synuclein and LC3-II western blot analysis of T lymphocyte
lysates. Blots shown are representative of independent experiments performed in T lymphocytes from healthy donors (HDs; n¼ 50). (b) Densitometry analysis of a-syn and
LC3-II levels relative to b-actin is shown (median with range is presented). (c) Correlation and linear regression analysis of a-syn and LC3-II levels relative to b-actin,
r¼  0.55, Po0.0001. (d) Alpha-synuclein and LC3-II western blot analysis of cell lysate from T lymphocytes obtained from 1 out of 10 patients with lymphoma. Two time
points are shown, that is, before (t0) and after 1 month (t1) of therapy with the multikinase inhibitor sorafenib. (e) Densitometry analysis of a-syn and LC3-II in patients (n¼ 10)
before (t0) and after 1 month (t1) of therapy is shown. Values are expressed as means±S.D. *Po0.05. ctr, control; r, Spearman’s rho
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a-synuclein could represent a useful predictive marker of the
therapeutic response to autophagy-modulating drugs.
Finally, this study opens new perspectives for therapeutic
strategies in those immune diseases characterized by
autophagy impairment, such as SLE, by reducing a-synuclein
synthesis and aggregation or by increasing a-synuclein
clearance, for example, developing small-molecule inhibitors
of a-synuclein assembly.1,33,34
Materials and Methods
Blood samples. Blood samples were obtained from 60 healthy donors
(35 women and 25 men; median age of 38 years (range 21–66 years)) and from
10 patients with SLE (7 women and 3 men; median age of 40 years (range 24–55
years)) attending the Lupus Clinic of ‘La Sapienza’ University of Rome, Italy. All SLE
patients fulfilled the American College of Rheumatology revised criteria for the
classification of SLE.35 Clinical characteristics of lymphoma patients (n¼ 10) were
previously reported.21 Peripheral blood lymphocytes from six patients with PD,
randomly selected from the patients admitted to the ‘Laboratory of Clinical and
Behavioral Neurology’ of Fondazione Santa Lucia, Rome, and to the Movement
Disorder Unit, Sant’Andrea Hospital ‘La Sapienza’ University of Rome, Italy.
Informed consent was obtained from all participants and the local ethic committee
approved the study.
Cell purification and cell cultures. Peripheral blood mononuclear cells
were isolated by Ficoll–Hypaque density-gradient centrifugation. Cells were
cultured in RPMI-1640 (Gibco BRL, Grand Island, NY, USA) medium with 10%
FBS (Thermo Scientific, Waltham, MA, USA), supplemented with 2 mM glutamine
(EuroClone, Pero, Milan, Italy) and 50 mg/ml gentamycin (EuroClone). Immuno-
magnetic negative selection kit from Miltenyi (Miltenyi Biotec, Bergisch-Gladbach,
Germany) was used to purify CD3þ T lymphocytes from peripheral blood
mononuclear cells. Purity of isolated cells, assessed by flow cytometer, reached
routinely at least 97%. For serum-starvation experiments, cells were cultured in
RPMI-1640 medium supplemented with 1% FBS for 4 h (time chosen on the basis
of preliminary time course experiments for 2–24 h; data not shown). Where
indicated, cells were treated in the presence of lysosomal inhibitors E64d and
pepstatin A (both at 10mg/ml; Sigma-Aldrich, St. Louis, MO, USA) for 2 h before
the end of culture. For inhibition of autophagy, cells were treated with 10 mM
3-methyladenine (Sigma-Aldrich) during the 4 h of serum starvation.
RNA interference transfection in human T lymphocytes. The
silencing of a-synuclein was performed with a chemically synthesized siRNA
(50-AACAGTGGCTGAGAAGACCAA-30; Qiagen, Milan, Italy) and a control siRNA
(Qiagen) with a random sequence not present in the human genome (50-AATTCT
CCGAACGTGTCACGT-30).36 107 T lymphocytes, resuspended in 100ml of the
Amaxa Nucleofector kit solution (Lonza, Walkersville, MD, USA), were electro-
porated with 5mg of the indicated siRNA using the V-024 program of the
Nucleofector (Amaxa Biosystems, Gaithersburg, MD, USA). Cells were then
incubated in complete medium for 24 h before harvesting and the level of
a-synuclein silencing was analyzed by both flow cytometry and western blot
analyses. For ATG5 silencing, the specific siRNA 50-AACCTTTGGCCTAAGAAGA-30
(Qiagen) was used.
Flow cytometry. Intracellular phenotyping of purified T cells was performed
as previously described.37 Briefly, cells were fixed with 4% paraformaldehyde,
permeabilized with FACS permeabilizing solution (BD BioSciences, San Jose, CA,
USA; 340973), washed and stained. Alpha-synuclein expression was detected
using anti-a-synuclein (1 mg 106 cells, Sigma, St. Louis, MO, USA; S5566)
monoclonal antibody (mAb) and FITC-conjugated anti-mouse IgG (Fab specific,
Sigma, F2653) as a secondary antibody. An appropriate isotype control antibody
(Sigma, M5409) was used. Acquisition was performed on a FACSCalibur
(BD BioSciences) and data were analyzed using the CellQuest Pro software
(BD BioSciences).
SDS-PAGE and western blot. Purified T lymphocytes were lysed in RIPA
buffer (100 mM Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100, 1 mM MgCl2) in the
presence of complete protease-inhibitor mixture. Protein content was determined
by the Bradford assay (Bio-Rad Laboratories, Richmond, CA, USA). For
a-synuclein detection, lymphocyte lysate (30 mg) was loaded in SDS-PAGE.
As a-synuclein monomers tend to easily detach from blotted membranes, resulting
in no or very poor detection, after western blot analysis, nitrocellulose membrane
was fixed by incubation for 30 min with Tris-buffered saline containing 0.4%
paraformaldehyde.38 As primary antibody, a mouse mAb specific to a-synuclein
(Sigma-Aldrich) was used. For LC3-II, p62 and NBR1 protein detection, rabbit anti-
human LC3B (Cell Signaling Technology, Beverly, MA, USA), rabbit anti-human
p62/SQSTM1 (Sigma-Aldrich) and rabbit anti-human NBR1 (Cell Signaling
Technology) antibodies were used. Peroxidase-conjugated goat anti-rabbit IgG
(Bio-Rad Laboratories) or anti-mouse IgG (Bio-Rad Laboratories) was used as
secondary antibodies and the reactions were developed using the ECL Prime
Western Blotting Detection Reagent (GE Healthcare, Pittsburgh, PA, USA). To
ensure the presence of equal amounts of protein, the membranes were reprobed
with a rabbit anti-human b-actin antibody (Sigma-Aldrich). Quantification of protein
expression was performed by densitometry analysis of the autoradiograms
(GS-700 Imaging Densitometer, Bio-Rad Laboratories).
Immunofluorescence experiments. An indirect immunofluorescence
assay was developed on peripheral blood T lymphocytes. Cells were fixed with
4% paraformaldehyde and permeabilized with 0.1% Triton X-100. After washing
with PBS, cells were incubated for 1 h with a rabbit anti-human LC3B (Cell
Signaling Technology) antibody and a mouse anti-a-synuclein mAb (Sigma). Alexa
Fluor 488-conjugated anti-rabbit IgG (Life Technologies, Carlsbad, CA, USA) and
Alexa Fluor 594-conjugated anti-mouse IgG (Life Technologies) were used as
secondary antibodies. For nuclear staining, the Hoechst 33258 dye (Sigma-
Aldrich) was used. Samples were analyzed by using an Olympus U RFL
microscope (Olympus, Tokyo, Japan). Images were acquired using a Hamamatsu
digital camera.
Ultrastructural analyses. For transmission electron microscope examina-
tion, cells were fixed in 2.5% cacodylate-buffered (0.2 M, pH 7.2) glutaraldehyde
(TAAB Laboratories, Berkshire, UK) for 20 min at room temperature and post-fixed
in 1% OsO4 (Electron Microscopy Sciences, Hatfield, PA, USA) in cacodylate
buffer for 1 h at room temperature. Fixed specimens were dehydrated through a
graded series of ethanol solutions and embedded in Agar 100 (Electron
Microscopy Sciences). Ultrathin sections were collected on 200-mesh grids and
counterstained with uranyl acetate (Electron Microscopy Sciences) and lead
citrate. Sections were observed with a Philips 208 electron microscope at 80 kV
(Philips, Eindhoven, Netherlands). Morphometric analyses were carried out on the
basis of previously proposed methodology.39 Forty cell sections per condition were
examined at the same magnification ( 8000) on different 300 mesh grids
obtained from different resin blocks in order to avoid counting the same cell
several times. We evaluated the number of cells displaying at least two frankly
autophagic vacuoles. In particular, vacuoles characterized by a double membrane,
barely detectable in lymphocytes, or by the absence of ribosomes in cytosolic side
of the vacuole, that is, excluding rough endoplasmic reticulum vesicles, and,
mainly, vacuoles containing organelle remnants or semi-digested materials were
considered (see Supplementary Figure 4). Only cells displaying intact
mitochondria were taken into account. At least 50 different cells were evaluated.
Statistical analysis. Results were analyzed on SPSS Inc. (Chicago, IL, USA;
version 14.0). The Mann–Whitney unpaired test was used to compare
quantitative variables in different groups. Spearman’s rank correlation coefficient
was applied for calculation of the correlation between parallel variables in single
samples. Linear regression analysis was used to display a best fit line to the
data. For morphometric analyses, the values found in control and specific
siRNA-transfected cells were analyzed by using paired t-test. P valueso0.05
were considered as significant.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. This study was partially supported by grants from AIRC
to WM (MCO – 9998 and 11505) and from the Italian Ministry of Health to EO (U7A).
CC and LT are supported by Fondazione Italiana Sclerosi Multipla-FISM-Cod. 2011/
R/36 (Genova, Italy).
Alpha-synuclein in T-lymphocyte autophagy
T Colasanti et al
8
Cell Death and Disease
1. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of alpha-synuclein: from
structure and toxicity to therapeutic target. Nat Rev Neurosci 2013; 14: 38–48.
2. Kim S, Jeon BS, Heo C, Im PS, Ahn TB, Seo JH et al. Alpha-synuclein induces apoptosis
by altered expression in human peripheral lymphocyte in Parkinson’s disease. FASEB J
2004; 18: 1615–1617.
3. Shin EC, Cho SE, Lee DK, Hur MW, Paik SR, Park JH et al. Expression patterns of
alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental
stages. Mol Cells 2000; 10: 65–70.
4. Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. Alpha-synuclein oligomers and
clinical implications for Parkinson disease. Ann Neurol 2013; 73: 155–169.
5. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles
of alpha-synuclein in neurological disorders. Lancet Neurol 2011; 10: 1015–1025.
6. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a
decade. Nat Rev Mol Cell Biol 2007; 8: 931–937.
7. Mizushima N, Klionsky DJ. Protein turnover via autophagy: implications for metabolism.
Annu Rev Nutr 2007; 27: 19–40.
8. Engelender S. Ubiquitination of alpha-synuclein and autophagy in Parkinson’s disease.
Autophagy 2008; 4: 372–374.
9. Martinez-Vicente M, Vila M. Alpha-synuclein and protein degradation pathways in
Parkinson’s disease: a pathological feed-back loop. Exp Neurol 2013; 247: 308–313.
10. Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA et al.
Alpha-synuclein impairs macroautophagy: implications for Parkinson’s disease. J Cell Biol
2010; 190: 1023–1037.
11. McLeod IX, Jia W, He YW. The contribution of autophagy to lymphocyte survival and
homeostasis. Immunol Rev 2012; 249: 195–204.
12. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011;
469: 323–335.
13. Pierdominici M, Vomero M, Barbati C, Colasanti T, Maselli A, Vacirca D et al. Role of
autophagy in immunity and autoimmunity, with a special focus on systemic lupus
erythematosus. FASEB J 2012; 26: 1400–1412.
14. Zhou XJ, Zhang H. Autophagy in immunity: implications in etiology of autoimmune/
autoinflammatory diseases. Autophagy 2012; 8: 1286–1299.
15. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses.
Immunity 2013; 39: 211–227.
16. Alessandri C, Barbati C, Vacirca D, Piscopo P, Confaloni A, Sanchez M et al.
T lymphocytes from patients with systemic lupus erythematosus are resistant to induction
of autophagy. FASEB J 2012; 26: 4722–4732.
17. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3:
542–545.
18. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al.
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy
2012; 8: 445–544.
19. Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano P. Alpha-synuclein aggregation
and cell death triggered by energy deprivation and dopamine overload are counteracted by
D2/D3 receptor activation. J Neurochem 2008; 106: 560–577.
20. Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW et al. Targeting autophagy enhances
sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy
2011; 7: 1159–1172.
21. Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C et al. Phase II
study of sorafenib in patients with relapsed or refractory lymphoma. Br J Haematol 2012;
158: 108–119.
22. Manzoni C, Lewis PA. Dysfunction of the autophagy/lysosomal degradation pathway is a
shared feature of the genetic synucleinopathies. FASEB J 2013; 27: 3424–3429.
23. Gerland LM, Genestier L, Peyrol S, Michallet MC, Hayette S, Urbanowicz I et al.
Autolysosomes accumulate during in vitro CD8þ T-lymphocyte aging and may participate
in induced death sensitization of senescent cells. Exp Gerontol 2004; 39: 789–800.
24. Phadwal K, Alegre-Abarrategui J, Watson AS, Pike L, Anbalagan S, Hammond EM et al. A
novel method for autophagy detection in primary cells: impaired levels of macroautophagy
in immunosenescent T cells. Autophagy 2012; 8: 677–689.
25. He MX, He YW. A role for c-FLIP(L) in the regulation of apoptosis, autophagy, and
necroptosis in T lymphocytes. Cell Death Differ 2013; 20: 188–197.
26. Song JX, Lu JH, Liu LF, Chen LL, Durairajan SS, Yue Z et al. HMGB1 is involved in
autophagy inhibition caused by SNCA/alpha-synuclein overexpression: a process
modulated by the natural autophagy inducer corynoxine B. Autophagy 2013; 10: 144–154.
27. Huang J, Liu K, Yu Y, Xie M, Kang R, Vernon P et al. Targeting HMGB1-mediated
autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 2012; 8: 275–277.
28. Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy
by caspase-mediated cleavage of Beclin 1. Oncogene 2010; 29: 1717–1719.
29. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis,
autophagy and the cross-talk between them. Cell Death Differ 2009; 16: 966–975.
30. Nagy G, Koncz A, Perl A. T- and B-cell abnormalities in systemic lupus erythematosus.
Crit Rev Immunol 2005; 25: 123–140.
31. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and
normalizes T cell activation-induced calcium fluxing in patients with systemic lupus
erythematosus. Arthritis Rheum 2006; 54: 2983–2988.
32. Leslie LA, Younes A. Targeting oncogenic and epigenetic survival pathways in lymphoma.
Leuk Lymphoma 2013; 54: 2365–2376.
33. Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T et al. Small molecule
inhibitors of alpha-synuclein filament assembly. Biochemistry 2006; 45: 6085–6094.
34. Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK. Curcumin modulates
alpha-synuclein aggregation and toxicity. ACS Chem Neurosci 2013; 4: 393–407.
35. Hochberg MC. Updating the American College of Rheumatology revised criteria for the
classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
36. Habig K, Walter M, Stappert H, Riess O, Bonin M. Microarray expression analysis of human
dopaminergic neuroblastoma cells after RNA interference of SNCA–a key player in the
pathogenesis of Parkinson’s disease. Brain Res 2009; 1256: 19–33.
37. Colasanti T, Maselli A, Conti F, Sanchez M, Alessandri C, Barbati C et al. Autoantibodies to
estrogen receptor alpha interfere with T lymphocyte homeostasis and are associated with
disease activity in systemic lupus erythematosus. Arthritis Rheum 2012; 64: 778–787.
38. Lee BR, Kamitani T. Improved immunodetection of endogenous alpha-synuclein. PLoS
One 2011; 6: e23939.
39. Gros F, Arnold J, Page N, Decossas M, Korganow AS, Martin T et al. Macroautophagy is
deregulated in murine and human lupus T lymphocytes. Autophagy 2012; 8: 1113–1123.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution-NonCommercial-
NoDerivs 3.0 Unported License. The images or other third party
material in this article are included in the article’s Creative Commons
license, unless indicated otherwise in the credit line; if the material is
not included under the Creative Commons license, users will need to
obtain permission from the license holder to reproduce thematerial. To
view a copy of this license, visit http://creativecommons.org/licenses/
by-nc-nd/3.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
Alpha-synuclein in T-lymphocyte autophagy
T Colasanti et al
9
Cell Death and Disease
